Hospira on the Ball: Paying Attention to FDA Complaints Under New CEO
This article was originally published in RPM Report
Executive Summary
Hospira’s new CEO Mike Ball was charting a global expansion and touting a move into biosimilars. Then the lingering quality control discussions with FDA caught up with the company and forced their way to the top of his agenda. That may be an important step for the company in the long-term.